Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Environmental Analytics
Environmental and financial analysis dashboard for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Industry: MANUFACTURING
Company Overview for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Highlights
Showing data for FY2023
Operational Environmental Cost
$210m
Operational Environmental Cost Intensity
3.61%
Total Environmental Cost
$227m
Total Environmental Cost Intensity
3.90%
ΔOperational Environmental Cost (2020-2023)
$53m
Decoupling Rate (2020-2023)
-1.92%
Adjusted EBITDA
$852m
Adjusted EBITDA Margin
15%
Environmental cost statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 47.92% | 2.13% | -22.81% | ||
| 0.93% | 1.04% | 1.02% | 0.86% | |
| 5.95% | 21.34% | 8.76% | ||
| 2.48% | 1.99% | 2.33% | 2.75% | |
| $157m | $184m | $212m | $210m | |
| 17.35% | 14.76% | -0.86% | ||
| 3.41% | 3.02% | 3.36% | 3.61% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| -54.67% | -3.92% | 9519.43% | ||
| 0.01% | 0.00% | 0.00% | 0.29% | |
| 17.16% | 14.75% | 7.10% | ||
| 3.41% | 3.03% | 3.36% | 3.90% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2023
Integrated financial analysis
Highlights
Showing data for FY2023
Adjusted EBITDA Margin
15%
Adjusted EBIT Margin
7.48%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$4,612m | $6,097m | $6,302m | $5,816m | |
| 32.19% | 3.37% | -7.71% | ||
$3,513m | $4,737m | $5,173m | $4,755m | |
| 76.16% | 77.70% | 82.08% | 81.75% | |
$1,100m | $1,360m | $1,129m | $1,061m | |
| 23.84% | 22.30% | 17.92% | 18.25% | |
$846m | $1,073m | $794m | $645m | |
| 18.34% | 17.60% | 12.60% | 11.09% | |
| ENVIRONMENTAL COST DATA | ||||
$157m | $184m | $212m | $210m | |
| 3.41% | 3.02% | 3.36% | 3.61% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$942m | $1,175m | $918m | $852m | |
| 20.43% | 19.28% | 14.56% | 14.64% | |
$689m | $889m | $583m | $435m | |
| 14.94% | 14.57% | 9.24% | 7.48% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2023
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.86%
Scope 2 (% of Sales)
2.75%
Operational Environmental Cost Intensity
3.61%
Scope 3 (% of Sales)
0.29%
Total Environmental Cost Intensity
3.90%
Selected peer group
Showing data for FY2023
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | CN | $210m | 3.61% |
Loading similar companies data...
Industry distribution
Showing data for FY2023
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2023
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $179m | 55.16% | N/A | N/A |
Energy-related activities (3) | $0m | 0.01% | N/A | N/A |
Upstream transportation (4) | $42m | 12.88% | N/A | N/A |
Waste (5) | $3m | 0.97% | N/A | N/A |
Business travel (6) | $2m | 0.70% | N/A | N/A |
Commuting (7) | $1m | 0.36% | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $30m | 9.14% | N/A | N/A |
Processing of products (10) | $0m | 0.02% | N/A | N/A |
Use of products (11) | $16m | 4.82% | N/A | N/A |
Final treatment of products (12) | $52m | 15.95% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $324m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2023